Compare FRD & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRD | ACOG |
|---|---|---|
| Founded | 1965 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 110.4M |
| IPO Year | 1995 | N/A |
| Metric | FRD | ACOG |
|---|---|---|
| Price | $32.39 | $8.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 101.4K | 39.9K |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | $22.96 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $14.52 | $4.50 |
| 52 Week High | $37.97 | $10.88 |
| Indicator | FRD | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 78.57 |
| Support Level | $17.90 | $5.27 |
| Resistance Level | $37.97 | N/A |
| Average True Range (ATR) | 2.62 | 0.57 |
| MACD | -0.55 | 0.17 |
| Stochastic Oscillator | 23.70 | 95.34 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.